Table 2.
Risk assessment scores.
| Patients Characteristics | Khorana Score [18] | CATS Score [25] | PROTECHT Score [26] | CONKO Score [27] | ONKOTEV Score [28] |
|---|---|---|---|---|---|
| Pancreatic or gastric cancer | +2 | +2 | +2 | +2 | - |
| Lung, gynecologic, or genitourinary cancer (except prostate), or lymphoma | +1 | +1 | +1 | +1 | - |
| Hemoglobin < 10 g/dL* or use of red cell growth factors | +1 | +1 | +1 | +1 | - |
| White blood cell count > 11 × 109/L* | +1 | +1 | +1 | +1 | - |
| Platelet count ≥ 350 × 109/L* | +1 | +1 | +1 | +1 | - |
| Body mass index > 35 kg/m2 | +1 | +1 | +1 | - | - |
| D-dimers ≥ 1.44 μg/mL* | - | +1 | - | - | - |
| P-selectin ≥ 53.1 ng/mL* | - | +1 | - | - | - |
| Gemcitabine or platinum chemotherapy | - | - | +1 | - | - |
| WHO performance status ≥ 2 | - | - | - | +1 | - |
| Khorana score ≥ 2 points | - | - | - | - | +1 |
| Metastatic disease | - | - | - | - | +1 |
| Previous venous thromboembolism | - | ¬- | - | - | +1 |
| Vascular/lymphatic macroscopic compression | - | - | - | - | +1 |
| High risk ≥3 Intermediate risk 1–2 Low risk 0 |
|||||
* values measured before the beginning of chemotherapy.